{"id":"octamoxin","rwe":[],"tags":[{"label":"octamoxin","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"nimaol","offLabel":[],"synonyms":["nimaol","octamoxin","2-Hydrazinooctane","octamoxine"],"timeline":[],"approvals":[],"brandName":"Nimaol","ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"octamoxin","explanation":"Unfortunately, the exact mechanism of action of Nimaol is not well understood, but it is thought to involve binding to a specific protein or receptor in the body. This binding can alter the activity of the protein or receptor, leading to changes in the body's normal functioning. As a result, Nimaol may help to treat certain conditions by modifying the body's response to a particular stimulus.","oneSentence":"Nimaol works by interacting with a specific target in the body to produce its therapeutic effect.","technicalDetail":"Nimaol's mechanism of action is likely to involve competitive inhibition of a specific enzyme or receptor, although the exact details of this process are not yet fully understood."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Octamoxin","title":"Octamoxin","extract":"Octamoxin, also known as 2-octylhydrazine, is an irreversible and nonselective monoamine oxidase inhibitor (MAOI) of the hydrazine class that was used as an antidepressant in the 1960s but is now no longer marketed."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/3800","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=OCTAMOXIN","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://en.wikipedia.org/wiki/Octamoxin","fields":["history","overview"],"source":"Wikipedia"}],"_enrichedAt":"2026-03-30T13:03:46.764391","biosimilars":[],"competitors":[],"genericName":"octamoxin","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"0HXY3M6S54","CHEBI":"CHEBI:134768","INN_ID":"1776","UMLSCUI":"C2825396","ChEMBL_ID":"CHEMBL2104528","DRUGBANK_ID":"DB09249","PUBCHEM_CID":"20811"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Other"],"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Nimaol, also known as OCTAMOXIN, is a small molecule drug of the octamoxin class. Its target and exact mechanism of action are unknown. It is not clear if Nimaol is FDA-approved or has any approved indications. The commercial status of Nimaol, including whether it is patented or generic, is also unknown. Further research is needed to understand the safety considerations and pharmacokinetic properties of Nimaol.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}